Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics

被引：0
作者：
Andreas A. Argyriou
Jordi Bruna
Armando A. Genazzani
Guido Cavaletti
机构：
[1] Saint Andrew's State General Hospital of Patras,Department of Neurology
[2] Unit of Neuro-Oncology,Department of Cell Biology
[3] Hospital Universitari de Bellvitge-ICO l'Hospitalet,Department of Pharmaceutical Sciences
[4] Bellvitge Institute for Biomedical Research (IDIBELL),undefined
[5] Hospital Duran i Reynals,undefined
[6] Physiology and Immunology,undefined
[7] Universitat Autònoma de Barcelona,undefined
[8] Centro de Investigación Biomédica en Red (CIBERNED),undefined
[9] Università del Piemonte Orientale,undefined
[10] Experimental Neurology Unit,undefined
[11] School of Medicine and Surgery and Milan Centre for Neuroscience,undefined
[12] School of Medicine — University of Milano-Bicocca,undefined
来源：
Nature Reviews Neurology | 2017年 / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Peripheral neurotoxicity is potentially permanent and ranks among the most common non-haematological adverse effects of chemotherapyIdentifying patients at high risk of chemotherapy-induced peripheral neurotoxicity (CIPN) is paramountThe identification of a clinical or genetic profile that can detect patients at high risk of CIPN still represents an unmet needThe methodology of pharmacogenetic studies on CIPN could be improvedFurther studies are warranted to identify genetic associations that could inform the management of patients with CIPN
引用
收藏
页码：492 / 504
页数：12
相关论文
共 105 条
[1]  
Argyriou AA(2007)Clinical and electrophysiological features of peripheral neuropathy induced by administration of cisplatin plus paclitaxel-based chemotherapy Eur. J. Cancer Care (Engl.) 16 231-237
[2]  
Argyriou AA(2010)Toxic peripheral neuropathy associated with commonly used chemotherapeutic agents J. BUON 15 435-446
[3]  
Zolota V(2014)Management of side effects in the personalized medicine era: chemotherapy-induced peripheral neuropathy Methods Mol. Biol. 1175 301-322
[4]  
Kyriakopoulou O(2012)Pharmacogenomics knowledge for personalized medicine Clin. Pharmacol. Ther. 92 414-417
[5]  
Kalofonos HP(2011)Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics Lancet Oncol. 12 1551-1561
[6]  
Alberti P(2014)Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature Cancer Manag. Res. 6 135-147
[7]  
Cavaletti G(2016)Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group clinical trials J. Clin. Oncol. 34 3014-3022
[8]  
Whirl-Carrillo M(2012)Adverse interactions between antifungal azoles and vincristine: review and analysis of cases Mycoses 55 290-297
[9]  
Cavaletti G(2006)Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support. Care Cancer 14 223-229
[10]  
Alberti P(2012)Factors exacerbating peripheral neuropathy induced by paclitaxel plus carboplatin in non-small cell lung cancer Oncol. Res. 20 179-185
12345678910